The confidence of rheumatologists about switching to biosimilars for their patients

Joint Bone Spine. 2018 Oct;85(5):507-509. doi: 10.1016/j.jbspin.2018.03.009. Epub 2018 Apr 6.

Authors

Guro L Goll¹, Espen A Haavardsholm², Tore K Kvien³

Affiliations

¹ Department of Rheumatology, Diakonhjemmet Hospital, Box 23 Vinderen, N-0319 Oslo, Norway.
² Department of Rheumatology, Diakonhjemmet Hospital, Box 23 Vinderen, N-0319 Oslo, Norway; Faculty of Medicine, University of Oslo, N-0319 Oslo, Norway.
³ Department of Rheumatology, Diakonhjemmet Hospital, Box 23 Vinderen, N-0319 Oslo, Norway; Faculty of Medicine, University of Oslo, N-0319 Oslo, Norway. Electronic address: [email protected].

PMID: 29631065
DOI: 10.1016/j.jbspin.2018.03.009

No abstract available

Keywords: Biosimilars; Disease-modifying antirheumatic drugs; Psoriatic arthritis; Rheumatoid arthritis; Spondyloarthritis; Switching.

Publication types

Editorial
Review

MeSH terms

Antirheumatic Agents / therapeutic use*
Arthritis, Psoriatic / diagnosis
Arthritis, Psoriatic / drug therapy*
Arthritis, Rheumatoid / diagnosis
Arthritis, Rheumatoid / drug therapy*
Attitude of Health Personnel
Biosimilar Pharmaceuticals / administration & dosage*
Clinical Competence*
Drug Substitution / trends*
Humans
Rheumatologists
Self Concept

Substances

Antirheumatic Agents
Biosimilar Pharmaceuticals